Last reviewed · How we verify
XT-150
At a glance
| Generic name | XT-150 |
|---|---|
| Also known as | IL-10 transgene plasmid DNA injected intrathecally |
| Sponsor | Xalud Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of XT-150 in Participants With ALS (PHASE1)
- Efficacy and Safety of XT-150 in Osteoarthritis of the Knee (PHASE2)
- Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain (PHASE2)
- Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain (PHASE1)
- Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis (PHASE1, PHASE2)
- Follow on Extension of XT-150-1-0201 (PHASE1)
- Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain (PHASE1)
- Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XT-150 CI brief — competitive landscape report
- XT-150 updates RSS · CI watch RSS
- Xalud Therapeutics, Inc. portfolio CI